Intelliject Inc. has entered into an exclusive license agreement with Sanofi-Aventis U.S. for a novel epinephrine auto-injector. Under the agreement, Sanofi-Aventis will be responsible for the manufacturing and commercialization of the device in U.S. and Canada, while Intelliject will be responsible for on-going development and obtaining U.S. regulatory approval and has certain promotion rights.

Sanofi-Aventis will make an initial up-front payment of $25 million. Intelliject will also be eligible to receive development and commercial milestones up to $205 million and tiered double-digit royalties on sales of any products commercialized under the license.